Drug intelligence / Profile preview

ZYSM006

Development stage: Preclinical
Lead developer: Yantai Rongchang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ZYSM006 is a preclinical small molecule therapeutic being developed by Yantai Rongchang Pharmaceutical for the treatment of solid tumors. As of late 2026, the asset is in the lead optimization and preclinical candidate (PCC) selection stage. While the specific biological target and mechanism of action remain undisclosed by the sponsor, it is part of Rongchang's expanding oncology pipeline, which includes other small molecule inhibitors such as the Pan-RAS inhibitor RCZY690 (ZYSM003).

Other names: ZYSM006ZYSM-006ZYSM 006

Beyond the preview

Go deeper on ZYSM006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZYSM006.

Explore the full profile